301 related articles for article (PubMed ID: 15481440)
1. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
Rüter B; Wijermans PW; Lübbert M
Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Claus R; Almstedt M; Lübbert M
Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
4. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.
Müller CI; Rüter B; Koeffler HP; Lübbert M
Curr Pharm Biotechnol; 2006 Oct; 7(5):315-21. PubMed ID: 17076647
[TBL] [Abstract][Full Text] [Related]
5. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
7. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
8. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.
Szmigielska-Kapłon A; Robak T
Curr Cancer Drug Targets; 2011 Sep; 11(7):837-48. PubMed ID: 21762079
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic targets in hematopoietic malignancies.
Claus R; Lübbert M
Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
15. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Vartholomatos G
Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
[TBL] [Abstract][Full Text] [Related]
16. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
19. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
[Next] [New Search]